Subsequently, we investigated whether LCs from melanoma SLNs were still able to reach a mature immunophenotype with CD83 up-regulation by fluorescent immunocytochemistry and flow cytometry (n = 5 negative SLNs from n = 5 patients) (Figure 4). The gene discussed is CD83; the disease is melanoma.